K. Takezawa

发表

MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations

I. Okamoto, H. Yamaguchi, J. Tanizaki, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer

Kazuko Sakai, Kazuhiko Nakagawa, Kaoru Tanaka, 2012, Clinical Cancer Research.

Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition

M. Fukuoka, K. Nishio, K. Yanagihara, 2010, Molecular Cancer Therapeutics.

Molecular Cancer Therapeutics Identification of cSrc as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to cSrc Inhibition

M. Fukuoka, K. Nishio, K. Yanagihara, 2010 .

Large Cell Neuroendocrine Carcinoma of the Mediastinum with -Fetoprotein Production

Kaoru Tanaka, I. Okamoto, J. Fukuoka, 2008 .

Large cell neuroendocrine carcinoma of the mediastinum with alpha-fetoprotein production.

M. Fukuoka, Kaoru Tanaka, H. Yoon, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cisplatin and etoposide chemotherapy combined with early concurrent twice-daily thoracic radiotherapy for limited-disease small cell lung cancer in elderly patients.

Y. Nishimura, M. Fukuoka, I. Okamoto, 2010, Japanese journal of clinical oncology.

A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer

Y. Nishimura, M. Fukuoka, K. Azuma, 2013, Investigational New Drugs.

Identification of thymidylate synthase as a potential therapeutic target for lung cancer

M. Fukuoka, J. Uchida, I. Okamoto, 2010, British Journal of Cancer.

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs

M. Fukuoka, M. Sasamata, I. Okamoto, 2010, British Journal of Cancer.

Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel.

T. Tsuruo, Shigeo Sato, S. Sato, 1999, Cancer research.

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells

P. Jänne, P. Janne, K. Azuma, 2012, British Journal of Cancer.

Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer

P. Jänne, K. Nishio, I. Okamoto, 2011, Clinical Cancer Research.

Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.

M. Fukuoka, I. Okamoto, K. Takezawa, 2010, Cancer research.

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.

M. Ladanyi, M. Kris, W. Pao, 2012, Cancer discovery.

A Novel Mass Spectrometry–Based Assay for Diagnosis of EML4-ALK–Positive Non–Small Cell Lung Cancer

K. Nishio, I. Okamoto, K. Takezawa, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.

Kaoru Tanaka, K. Nishio, I. Okamoto, 2010, Cancer research.

Synergistic Antitumor Effect of S-1 and HER2-Targeting Agents in Gastric Cancer with HER2 Amplification

M. Fukuoka, J. Uchida, I. Okamoto, 2010, Molecular Cancer Therapeutics.

Molecular Cancer Therapeutics Synergistic Antitumor Effect of S-1 and HER 2-Targeting Agents in Gastric Cancer with HER 2 Amplification

M. Fukuoka, J. Uchida, I. Okamoto, 2010 .

Cell Lung Cancer Small − Positive Non − Resistance to ALK Inhibitors in EML 4-ALK Activation of HER Family Signaling as a Mechanism of Acquired

Kaoru Tanaka, K. Nishio, I. Okamoto, 2013 .

Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase–Targeted Agents in Non–Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor

M. Fukuoka, K. Nishio, I. Okamoto, 2010, Molecular Cancer Therapeutics.

HER2 Amplifi cation: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR

M. Ladanyi, M. Kris, E. Stanchina, 2012 .

HER 2 Amplifi cation : A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFR T 790 M Mutation

M. Ladanyi, M. Kris, E. Stanchina, 2012 .

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer

K. Nishio, I. Okamoto, H. Yamaguchi, 2011, British Journal of Cancer.

Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis.

M. Fukuoka, I. Okamoto, K. Takezawa, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer

Kaoru Tanaka, K. Nishio, I. Okamoto, 2012, Clinical Cancer Research.

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.

M. Ladanyi, M. Kris, W. Pao, 2012, Cancer discovery.